Industry Briefs: Apr. 2, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: Apr. 2, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Albany Molecular Research has agreed to license to Bessor Pharma its tubulin-inhibitor program for treating cancer. Read More

A federal district court has ruled in favor of AstraZeneca on its formulation patent for Seroquel (quetiapine fumarate) extended-release tablets. Read More

BioStorage Technologies has expanded its services in the academic research sector throughout the northeast United States. Read More

Eisai and Minophagen Pharmaceutical have concluded a license agreement concerning the development and commercialization of the cutaneous T-cell lymphoma treatment bexarotene. Read More

Gerresheimer has acquired Neutral Glass. Read More

GlaxoSmithKline has agreed to purchase 10 million shares to increase its ownership in Theravance. Read More

Illumina’s board of directors has unanimously rejected Roche’s revised offer to acquire the company for $51 per share in cash. Read More

Pharmaceutical Research and Manufacturers of America has issued a statement to support the National Governor’s Association’s Prescription Drug Abuse Reduction Policy Academy. Read More

Sigma Aldrich has acquired Research Organics. Read More

People News

Laureate Biopharma has named Lisa Cozza as vice-president of business development. Read More

Merck has appointed Michael J. Holston as chief ethics and compliance officer, effective June 25, 2012. He will succeed Richard S. Bowles, who plans to retire from the company. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here